Compare XWEL & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XWEL | PCSA |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0M | 8.2M |
| IPO Year | 2010 | 2012 |
| Metric | XWEL | PCSA |
|---|---|---|
| Price | $1.16 | $2.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 187.9K | 62.7K |
| Earning Date | 05-19-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,210,000.00 | $5,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.26 | $0.11 |
| 52 Week High | $2.20 | $8.88 |
| Indicator | XWEL | PCSA |
|---|---|---|
| Relative Strength Index (RSI) | 48.81 | 45.97 |
| Support Level | $1.01 | $1.96 |
| Resistance Level | $1.26 | $3.26 |
| Average True Range (ATR) | 0.08 | 0.30 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 56.00 | 11.36 |
XWELL Inc is an international wellness organization dedicated to delivering restorative and health-focused services to travelers through its three reportable operating segments: XpresSpa, XpresTest, and Naples Wax Center. The XpresSpa segment, which generates maximum revenue, operates spa service locations in airports, offering massage, skincare, and travel products. The XpresTest segment provides aircraft wastewater and passenger nasal sampling through the CDC's bio-surveillance program. The Naples Wax Center segment operates six locations offering face and body waxing, skincare services, and cosmetic products. The Company generates maximum revenue from the United States.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.